DEERFIELD, Ill., March 27 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation announced 2007 funding and application deadlines for its Renal Discoveries Extramural Grant Program (EGP), which is focused on patient- oriented research in academic nephrology training centers around the world. Four grants will be awarded and funded in 2007 - one each in Asia/Pacific, Latin America, North America and Europe/Middle East/Africa/Russia.
The program, which is designed to promote scientific advancement and training in the field of kidney disease, awards grants for innovation, exploration and application of research to advance the knowledge of renal insufficiency and its treatment. Grant recipients receive up to $375,000 over three years to conduct research that can be translated into clinical applications to improve care for patients with kidney disease. Research must be focused on dialytic therapies, chronic kidney disease (CKD), or co- morbidities associated with end-stage renal disease.
Each grant also includes funding for research fellowship training at the institutions conducting the research. The fellowship-training grant will support a minimum of one research fellow at the institution during the course of the grant period.
An independent international Medical Advisory Board, whose members represent a breadth of scientific knowledge, evaluates and scores each application. The deadline for applicants to submit a letter of intent is April 30, 2007. The full grant application deadline is September 7, 2007. Application information is available at http://www.baxter.com/egp .
Renal Discoveries continues Baxter’s support of the study of kidney disease by building on previous grants that distributed more than $30 million to 247 researchers from 26 countries since 1989. The program has provided resources to enable scientific researchers to pursue broad, long-term basic and applied studies. Such studies are critical to enhancing the collective knowledge base on kidney disease and treatment.
“Renal Discoveries supports patient-oriented research because it provides the guiding knowledge needed for innovation that is crucial to advancing treatment for CKD,” said Sarah S. Prichard, M.D., vice president of global medical/clinical affairs and research for Baxter’s Renal business. “It also helps to build a pipeline of investigators-in-training who will be future thought leaders in this area.”
Globally, there are a growing number of patients with CKD who require renal replacement therapy. Renal replacement therapy, in the form of dialysis or transplantation, is offered to CKD patients in more than 120 countries. Worldwide, almost 1.8 million people are receiving renal replacement therapy with 1.4 million on some form of dialysis treatment.
About BAXTER
Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. . Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients’ lives. For more information about Baxter, please visit http://www.baxter.com .
Baxter Healthcare Corporation
CONTACT: Media, Jerreau Beaudoin, +1-847-473-6588, or Investors, Mary KayLadone, +1-847-948-3371, or Clare Trachtman, +1-847-948-3085, all forBaxter Healthcare Corporation
